Skip to main content

Adenosine - All you need to know !!!

Adenosine


πŸ«€ Mechanism of Action of Adenosine – Explained Clearly


Adenosine is one of the most fascinating drugs in cardiology — a molecule that literally stops the heart for a moment to save it. Despite its short half-life (less than 10 seconds!), its physiological and therapeutic effects are profound. Let’s break down how this tiny nucleoside exerts such dramatic actions.



---


πŸ’Š What is Adenosine?


Adenosine is an endogenous purine nucleoside — a naturally occurring compound in the body derived from the breakdown of ATP (adenosine triphosphate). It plays roles in energy transfer, cell signaling, and modulation of cardiac and vascular function.


Clinically, adenosine is used mainly for:


Termination of paroxysmal supraventricular tachycardia (PSVT)


Diagnosis of tachyarrhythmias during electrophysiological testing


Assessment of coronary blood flow reserve in stress testing




---


⚙️ Mechanism of Action


Adenosine acts through specific adenosine receptors located on cardiac and vascular tissues. The main subtypes involved are A1 and A2A receptors.


1. A1 Receptor (Cardiac Effects)


Found mainly in the SA node, AV node, and atrial tissue.


Activation of A1 receptors → stimulates Gi protein → inhibits adenylyl cyclase → ↓ cAMP levels.


This leads to:


Opening of inward rectifier K⁺ channels (IK-Ado) → hyperpolarization of nodal cells.


Reduced calcium influx through L-type Ca²⁺ channels → decreased conduction and automaticity.




🫧 Result:


Slows AV nodal conduction (negative dromotropy)


Decreases SA nodal firing rate (negative chronotropy)


Can transiently block AV conduction, which is the therapeutic mechanism used to terminate AVNRT or AVRT.




---


2. A2A Receptor (Vascular Effects)


Present in vascular smooth muscle, especially in coronary vessels.


Activation → Gs protein stimulation → increased cAMP → smooth muscle relaxation.



🩸 Result:


Vasodilation, especially coronary vasodilation, which helps in myocardial perfusion imaging and coronary flow assessment.




---


⚡ The Famous “Adenosine Pause”


When adenosine is administered intravenously (usually 6–12 mg rapid IV push), patients often experience a few seconds of asystole or AV block.

This is a transient electrophysiological pause — a reflection of the drug’s effect on the AV node — and is typically self-limited due to rapid degradation by adenosine deaminase in blood and tissues.



---


⏱️ Pharmacokinetics in a Flash


Onset: Within seconds


Half-life: < 10 seconds


Metabolism: Rapid uptake by RBCs and endothelial cells; deaminated to inosine


Elimination: Non-renal; enzymatic degradation



Because of its ultra-short half-life, continuous ECG monitoring is essential during administration.



---


πŸš‘ Clinical Summary


Effect Mechanism Clinical Use


AV nodal block A1 receptor activation → ↓ cAMP → ↓ Ca²⁺ influx Termination of AVNRT/AVRT

Vasodilation A2A receptor activation → ↑ cAMP → smooth muscle relaxation Coronary flow reserve testing

Transient bradycardia/asystole SA/AV node suppression Diagnostic in SVTs




---


⚠️ Precautions


Avoid in 2° or 3° AV block, sick sinus syndrome, or severe asthma (can trigger bronchospasm).


May interact with theophylline (antagonizes effect) and dipyridamole (potentiates effect).




---


🧠 Quick Recap


Adenosine = “Natural Heart Reset”


A1 → AV nodal suppression → Stops reentry tachycardia


A2A → Vasodilation → Useful for perfusion imaging


Rapid onset, ultrashort action, and complete reversibility




---


πŸ“Œ Key Takeaway


Adenosine’s power lies in its simplicity — a naturally occurring molecule that can pause the heart safely to restore rhythm. Its ability to selectively block AV nodal conduction without lasting effects makes it a cornerstone in emergency and diagnostic cardiology.



---


#Adenosine #Cardiology #MechanismOfAction #SVT #Pharmacology #HeartRhythm #CardiacDrugs #MedicalBlog #


For more stuff visit:

Www.Youtube.com/@DrMusmanJaved



Comments

Popular posts from this blog

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...